Android app on Google Play

Audeo Oncology (AURX) Files $60M IPO

July 6, 2012 4:21 PM EDT Send to a Friend
Get Alerts AURX Hot Sheet
Trade AURX Now!
Join SI Premium – FREE
Audeo Oncology (Nasdaq: AURX) filed a $60 million IPO on form S-1 with the SEC after the close Friday. The company plans to list its common stock on The Nasdaq Global Market under the symbol "AURX."

Underwriters are Leerink Swann and Oppenheimer & Co.

Audeo Oncology is a late stage biopharmaceutical company primarily focused on utilizing our Hyaluronic Acid Chemotransport Technology, or HyACT, to target cancer drugs preferentially to tumor cells to enhance drug activity. HyACT is a flexible platform technology designed to increase the effectiveness of anti-cancer agents without increasing treatment toxicity. The company seek to reduce the risks related to drug development by using known anti-cancer drugs, and aim to enhance their commercial value by improving their effectiveness.

You May Also Be Interested In

Related Categories


Related Entities


Add Your Comment